Anika Therapeutics
Anika Therapeutics (NASDAQ: ANIK) is a Bedford, MA-based medical device company that develops and commercializes hyaluronic acid-based regenerative and osteoarthritis pain management products for orthopedic surgeons, sports medicine physicians, and OA patients across 45+ countries, operating through direct sales and OEM channels.
- Company typePublic
- Founded1992
- HeadquartersBedford, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Anika Therapeutics does
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a Bedford, Massachusetts-based medical device company founded in 1992 that develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair, built on a proprietary hyaluronic acid (HA) technology platform with 30+ years of domain expertise. The company operates two product franchises: Regenerative Solutions (Integrity HA-based rotator cuff and tendon repair implant, Hyalofast cartilage regeneration scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation, and the RevoMotion Reverse Shoulder Arthroplasty System) and Osteoarthritis Pain Management (Cingal combination HA+steroid single injection, Monovisc single-injection HA viscosupplement, Orthovisc multi-injection HA viscosupplement). Products are available in 45+ countries worldwide.
Anika serves orthopedic surgeons, sports medicine physicians, and osteoarthritis patients through a dual-channel commercial model. The Commercial Channel uses direct enterprise field sales and physician engagement, targeting healthcare providers and growing 22% in Q4 2025 with 10%-20% projected growth for 2026. The OEM Channel supplies HA-based products to large medical device manufacturers (notably J&J MedTech) for incorporation into their portfolios, though this channel is under pricing pressure and declined 12% in Q4 2025. The company also markets to patients via a Find a Doctor locator tool and medical education content.
Anika monetizes through one-time product sales across both channels. FY2025 revenue was $112.8M (down 6% YoY), with Q1 2026 at $29.6M (up 13% YoY) and FY2026 guidance of $114M-$122.5M. Strategic priorities include advancing the Hyalofast PMA toward FDA approval, scaling the Integrity and RevoMotion product lines, restructuring costs (~$2.5M annualized adjusted EBITDA savings), and completing a $15M share repurchase program. The Arthrosurface joint preservation business was divested in October 2024 to refocus on core HA-based regenerative and OA pain management offerings.
Anika Therapeutics firmographics
Firmographics- Name
- Anika Therapeutics
- Legal name
- Anika Therapeutics, Inc.
- Website
- https://anikatherapeutics.com
- Company type
- Public
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Anika Therapeutics (NASDAQ: ANIK) is a Bedford, MA-based medical device company that develops and commercializes hyaluronic acid-based regenerative and osteoarthritis pain management products for orthopedic surgeons, sports medicine physicians, and OA patients across 45+ countries, operating through direct sales and OEM channels.
- Ownership category
- akta.pro rank
Anika Therapeutics industry classification
Industry- Product category
- Orthopedic Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)
- akta.pro secondary industries
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Pain Management (Spine & Musculoskeletal) (HLAKALAM)
Keywords
Where Anika Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Bedford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Anika Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Product Sales - Commercial Channel: Direct sales of orthopedic regenerative solutions and osteoarthritis pain management products to healthcare providers and through distribution networks. Commercial Channel revenue was $13.3 million in Q4 2025, growing 22% year-over-year. Expected to grow 10%-20% in 2026.
- Product Sales - OEM Channel: Sales to original equipment manufacturer partners including J&J MedTech. OEM Channel faced 12% decline in Q4 2025 due to pricing pressures. The channel is expected to continue facing headwinds from J&J MedTech pricing pressures.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Anika Therapeutics product offering
Product offeringCore offering
Anika Therapeutics develops, manufactures, and commercializes therapeutic products based on a proprietary hyaluronic acid (HA) technology platform for orthopedic tissue protection, healing, and repair. Its portfolio spans Regenerative Solutions (Integrity tendon repair implant, Hyalofast cartilage scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation) and Osteoarthritis Pain Management (Cingal, Monovisc, Orthovisc viscosupplements), supplemented by the RevoMotion Reverse Shoulder Arthroplasty System. Products are sold to orthopedic surgeons and healthcare providers via a Commercial direct sales channel and to large OEMs such as J&J MedTech via an OEM channel, distributed across 45+ countries.
Product overview
Anika Therapeutics offers a comprehensive portfolio of hyaluronic acid-based orthopedic products organized into two main categories: Regenerative Solutions and Osteoarthritis (OA) Pain Management. The Regenerative Solutions portfolio includes Integrity (hyaluronic acid implant for rotator cuff and tendon repair), Hyalofast (cartilage regeneration scaffold), Tactoset (injectable bone substitute), and NanoFx (advanced bone marrow stimulation). The OA Pain Management portfolio features Cingal (combination HA and steroid single injection), Monovisc (single-injection HA viscosupplement), and Orthovisc (multi-injection HA viscosupplement). The company also launched the RevoMotion Reverse Shoulder Arthroplasty System in February 2024. All products leverage the company's proprietary hyaluronic acid technology platform and are available in over 45 countries worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Integrity: Rotator cuff and tendon repair augmentation implant system
- Hyalofast
- Tactoset
- NanoFx
- Cingal
- Monovisc
- Orthovisc
Products and services
- Integrity Hyaluronic acid-based implant for rotator cuff and tendon repair augmentation. Enhances strength and biological support in rotator cuff repairs with demonstrated thickening of rotator cuff repair in postoperative imaging. For orthopedic surgeons performing rotator cuff and tendon repair procedures.
- Hyalofast Cartilage regeneration scaffold using hyaluronic acid technology for single-stage cartilage repair procedures. Completed Phase III FastTRACK clinical trial; PMA filing submitted to FDA in October 2025. For orthopedic surgeons treating patients with cartilage defects.
- Tactoset Injectable bone substitute product for orthopedic regenerative procedures. For orthopedic surgeons performing bone substitute / void filling procedures.
- NanoFx Advanced bone marrow stimulation product for orthopedic repair procedures. For orthopedic surgeons performing bone marrow stimulation techniques.
- Cingal Next generation combination hyaluronic acid and steroid single injection for osteoarthritis pain management, providing immediate pain relief lasting up to 6 months, reducing stiffness and improving function; helps postpone knee replacement surgery. For healthcare providers treating osteoarthritis pain.
- Monovisc Single-injection hyaluronic acid viscosupplement for osteoarthritis pain management. For healthcare providers treating osteoarthritis pain.
- Orthovisc Multi-injection hyaluronic acid viscosupplement for osteoarthritis pain management. For healthcare providers treating osteoarthritis pain.
- RevoMotion Reverse Shoulder Arthroplasty System Reverse shoulder arthroplasty system featuring the smallest diameter threaded baseplate on the market, targeting severe rotator cuff conditions. For orthopedic surgeons performing reverse shoulder arthroplasty.
Quantifiable outcome
- Integrity product line revenue more than doubled in 2025 after receiving 510(k) clearance in 2023
- +3 more outcomes
Companies that use Anika Therapeutics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Anika Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Anika Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Johnson & Johnson MedTechcoreJ&J MedTech is a key OEM customer for Anika's viscosupplementation products through the OEM Channel. The relationship involves supply of HA-based products for J&J's osteoarthritis pain management offerings. However, J&J MedTech has been imposing pricing pressures on Anika, contributing to a 12% decline in the OEM Channel in Q4 2025 and ongoing headwinds in 2026.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Anika Therapeutics competitors and assessment
Company assessmentDirect peers
- Seikagaku Corporation: Japanese specialty pharmaceutical company focused on hyaluronic acid-based products, including viscosupplements (Artz/SUPPARTZ) directly competing with Anika's Monovisc/Orthovisc/Cingal. Most direct comparable in HA technology platform and orthopedic pain management focus.
- Bioventus: Orthopedic regenerative medicine company offering viscosupplements (Durolane, Gelsyn-3) and bone graft substitutes, directly competing with Anika in OA pain management and cartilage/bone repair categories. Similar mid-cap, single-therapeutic-focus profile.
Broad incumbents
- Sanofi (CHC/Synvisc franchise): Markets the Synvisc/Synvisc-One line of hyaluronic acid viscosupplements, directly competing with Anika's Monovisc/Orthovisc/Cingal in the OA pain management category. Operates as part of Sanofi's broader specialty care/consumer health portfolio.
- Ferring Pharmaceuticals: Markets Euflexxa, a hyaluronic acid viscosupplement that directly competes with Anika's Monovisc and Orthovisc in the OA pain management space. Part of Ferring's broader specialty pharma portfolio.
- Stryker Corporation: Large diversified orthopedic medical device company with broad sports medicine and joint reconstruction portfolios. Competitor in shoulder/rotator cuff (where RevoMotion competes) and broader orthopedic surgical markets.
- Zimmer Biomet: Global orthopedic medical device leader across joint reconstruction, sports medicine, and biologics. Competes with Anika in shoulder arthroplasty and regenerative/orthobiologics adjacencies through its broader portfolio.
- Smith+Nephew: Global medical device company with significant sports medicine and orthobiologics portfolios. Competes with Anika in cartilage repair and joint preservation, particularly relevant as Anika scales Hyalofast and Integrity.
- Arthrex: Private orthopedic medical device leader in sports medicine and soft tissue repair. Direct competitor in rotator cuff repair augmentation (where Integrity competes) and cartilage restoration markets.
Others
- Johnson & Johnson MedTech (DePuy Synthes): Both Anika's largest OEM customer (for HA viscosupplements) and a competitor in shoulder reconstruction and sports medicine through DePuy Synthes/Mitek. Pricing pressure from this partner is a current headwind to Anika's OEM channel.
Emerging players
- CONMED Corporation: Mid-cap orthopedic and sports medicine company with a growing portfolio in rotator cuff repair, cartilage restoration, and biologics. Competes with Anika in similar surgical specialties with comparable commercial sales force scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Anika Therapeutics social profiles
Digital presenceAnika Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anika Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Anika Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anika Therapeutics M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anika Therapeutics
What does Anika Therapeutics do?
Anika Therapeutics develops, manufactures, and commercializes therapeutic products based on a proprietary hyaluronic acid (HA) technology platform for orthopedic tissue protection, healing, and repair. Its portfolio spans Regenerative Solutions (Integrity tendon repair implant, Hyalofast cartilage scaffold, Tactoset injectable bone substitute, NanoFx bone marrow stimulation) and Osteoarthritis Pain Management (Cingal, Monovisc, Orthovisc viscosupplements), supplemented by the RevoMotion Reverse Shoulder Arthroplasty System. Products are sold to orthopedic surgeons and healthcare providers via a Commercial direct sales channel and to large OEMs such as J&J MedTech via an OEM channel, distributed across 45+ countries.
Is Anika Therapeutics a public or private company?
Anika Therapeutics is a public company. It is classified as public and is currently operating.
When was Anika Therapeutics founded?
Anika Therapeutics was founded in 1992. It employs 251 to 500 people.
Where is Anika Therapeutics based?
Anika Therapeutics is headquartered in Bedford, United States, in the North America region.
How does Anika Therapeutics make money?
Two revenue lines are on record. Product Sales - Commercial Channel is the primary driver. The others are product Sales - OEM Channel.
Who are Anika Therapeutics's main competitors?
Direct peers on record are Seikagaku Corporation and Bioventus. Broad incumbents are Sanofi (CHC/Synvisc franchise), Ferring Pharmaceuticals, Stryker Corporation, Zimmer Biomet, Smith+Nephew and Arthrex. Johnson & Johnson MedTech (DePuy Synthes) is listed as an others. CONMED Corporation is listed as an emerging player.
Does Anika Therapeutics have an API?
No public API is recorded for Anika Therapeutics.
What industry is Anika Therapeutics in?
Anika Therapeutics's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.